COYA 302 treatment for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests an experimental treatment called COYA 302 for ALS. It aims to see if it can slow down the worsening of muscle weakness and improve daily function. It might be an option for people in the earlier stages of ALS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have ALS (sporadic or familial) that fits certain diagnostic criteria.
- Your symptoms must have started within the last 28 months.
- Your muscle function score (ALSFRS-R) must be at least 35 at the start.
- Your breathing capacity must be at least 60% of what is normal for you.
- If you take certain ALS medications (like riluzole, edaravone, or tofersen), you need to be on a stable dose or be willing to not start them during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This study tests an investigational oral medication, FHND1002, for people with ALS whose disease has been progressing for less than 2 years. It aims to slow further decline in muscle function and breathing ability.
This trial tests a new drug called VTx-002 to see if it is safe and tolerable for people with ALS. You may be able to join if you have had symptoms for less than 18 months and have a caregiver who can help.
This Phase 2 study tests whether dazucorilant can slow or improve outcomes in people with amyotrophic lateral sclerosis (ALS) who are likely to progress more quickly. You may be able to join if you meet specific ALS type and risk-score requirements and your health tests and medications fit the study rules.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.